A Personalized Approach to Chronic Kidney Disease and Cardiovascular Disease: JACC Review Topic of the Week

Cardiovascular Risk and Diseases

Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week

J Am Coll Cardiol

Cainzos-Achirica M, Glassner K, Zawahir HS, Dey AK, Agrawal T, Quigley EMM, Abraham BP, Acquah I, Yahya T, Mehta NN, Nasir K

doi: 10.1016/j.jacc.2020.10.027

Cardiovascular Risk and DiseasesHypertension

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis

JAMA Intern Med.

Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, Odden MC, Peralta CA, Cheung AK, Nadkarni GN, Coleman RL, Holman RR, Zanchetti A, Peters R, Beckett N, Staessen JA, Ix JH

doi: 10.1001/

Heart Failure

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease

JACC Heart Fail.

Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS

doi: 10.1016/j.jchf.2018.

Cardiovascular Risk and Diseases

Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

JAMA Cardiol

Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, Koenig W, Cannon CP, Budaj A, Hagström E, Siegbahn A, Wallentin L, STABILITY Investigators.

doi: 10.1001/jamacardio.2021.3079

Heart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and StrokeTherapy and Intervention

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

J Am Coll Cardiol.

Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH.

doi: 10.1016/j.jacc.2018.03.490.

Cardiovascular Risk and Diseases

Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week

J Am Coll Cardiol

Garshick MS, Ward NL, Krueger JG, Berger JS

doi: 10.1016/j.jacc.2021.02.009

Cardiovascular Risk and Diseases

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options

Circulation

Jankowski J, Floege J, Fliser D, Böhm M, Marx N

doi: 10.1161/CIRCULATIONAHA.120.050686

Myocardial Infarction

High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients

Am Heart J.

Fu EL, Franko MA, Obergfell A, Dekker FW, Gabrielsen A, Jernberg T, Carrero JJ

doi: 10.1016/j.ahj.2019.06.019.

Cardiac Arrest or DeathHeart, Artery and Coronary DiseasesHeart Failure

Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week

J Am Coll Cardiol

Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, Elliott PM, Hagege A, Kuusisto J, Linhart A, Nordbeck P, Olivotto I, Pietilä-Effati P, Namdar M

doi: 10.1016/j.jacc.2020.12.024

Related content

Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease

Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options

High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients

Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week